Gerald P. Linette
Gerald P. Linette has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Alfonsus J. M. van Den Eertwegh
Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1118, 1081 HZ Amsterdam, The Netherlands
1 shared publication - Allegra A. Petti
McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO, USA.
1 shared publication - Axel Hoos
GlaxoSmithKline, Collegeville, PA
1 shared publication - Beatriz M. Carreno
Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
1 shared publication - Christian Hermann Ottensmeier
University of Liverpool
1 shared publication - Céleste Lebbé
Université Paris Cite, AP-HP Dermato-oncology and CIC, Cancer Institute APHP.nord Paris cité, INSERM U1342—Equipe—CNRS EMR8000, Saint Louis Hospital, Paris, France
1 shared publication
Latest Publications
- Open Access
- 29 January 2016
- Published by Springer Nature in Genome Medicine
- Vol. 8 (1) , 1-11
pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens
Cancer immunotherapy has gained significant momentum from recent clinical successes of checkpoint blockade inhibition. Massively parallel sequence analysis suggests a connection between mutational load and response to this class of therapy. Methods to identify which tumor-specific mutant peptides (neoantigens) can elicit anti-tumor T cell immunity are needed to improve predictions of checkpoint therapy response and to identify targets for vaccines and adoptive T cell therapies. Here, we present a flexible, streamlined computational workflow for identification of personalized Variant Antigens by Cancer Sequencing (pVAC-Seq) that integrates tumor mutation and expression data (DNA- and RNA-Seq). pVAC-Seq is available at https://github.com/griffithlab/pVAC-Seq .
- 29 January 2016
- Published by Springer Nature in Genome Medicine
- Vol. 8 (1) , 1-11
Open AccesspVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens
Cancer immunotherapy has gained significant momentum from recent clinical successes of checkpoint blockade inhibition. Massively parallel sequence analysis suggests a connection between mutational load and response to this class of therapy. Methods to identify which tumor-specific mutant peptides (neoantigens) can elicit anti-tumor T cell immunity are needed to improve predictions of checkpoint therapy response and to identify targets for vaccines and adoptive T cell therapies. Here, we present a flexible, streamlined computational workflow for identification of personalized Variant Antigens by Cancer Sequencing (pVAC-Seq) that integrates tumor mutation and expression data (DNA- and RNA-Seq). pVAC-Seq is available at https://github.com/griffithlab/pVAC-Seq .
- Open Access
- 1 January 2012
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 10 (1) , 66
Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment
In an international, randomized Phase III trial ipilimumab demonstrated a significant overall survival benefit in previously treated advanced melanoma patients. This report summarizes health-related quality of life (HRQL) outcomes for ipilimumab with/without gp100 vaccine compared to gp100 alone during the clinical trial’s 12 week treatment induction period.
- 1 January 2012
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 10 (1) , 66
Open AccessHealth related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment
In an international, randomized Phase III trial ipilimumab demonstrated a significant overall survival benefit in previously treated advanced melanoma patients. This report summarizes health-related quality of life (HRQL) outcomes for ipilimumab with/without gp100 vaccine compared to gp100 alone during the clinical trial’s 12 week treatment induction period.